Silo Pharma Inc's Comment on Sales, Marketing and Customers
For the years ended December 31, 2025 and 2024, one licensee accounted for 100% of the company's total revenues from customer license fees. The company's vendor license agreements during this period were exclusively with two licensors, UMB and Columbia. The company operates in the rare disease therapeutics industry and faces competition from major pharmaceutical, specialty pharmaceutical, biotechnology companies, academic institutions, governmental agencies, and medical research organizations. Its products compete with existing standard-of-care treatments and emerging therapies. Competitors include established pharmaceutical, biopharmaceutical, and biotechnology firms with greater resources and experience, as well as smaller and early-stage companies, particularly those collaborating with larger companies. There is a growing number of companies focused on discovering new psychedelic compounds. The company and its vendors are subject to extensive government regulations, including those enforced by the FDA and other regulatory authorities, which govern all aspects of drug development, approval, and marketing.
Silo Pharma Advancing Research and Development with $2.1 Million Registered Direct OfferingSarasota, FL - Silo Pharma, Inc. (Nasdaq: SILO), a prominent biopharmaceutical company specializing in innovative drug delivery systems for traditional therapeutics and psychedelic treatments, is making significant strides in its mission to revolutionize the field of healthcare. The company recently announced a successful registered direct offering, priced at-the-market under Nasdaq rules, which will provide a boost to its research and development efforts.Under the offering, Silo Pharma has entered into definitive agreements for the purchase and sale of 763,638 shares of common stock at a purchase price of $2.75 per sh...
Silo Pharma Inc., a renowned pharmaceutical company, has recently secured an exclusive global license for a groundbreaking Alzheimer s therapeutic. This agreement is set to significantly bolster the company s intellectual property portfolio while making substantial contributions to the advancement of Alzheimer s research and patient care. Despite the minor downward trend in revenue, Silo Pharma s innovative strides continue to position them as a key player in the pharmaceutical industry.Enhancing the Intellectual Property PortfolioThe recently acquired exclusive global license stands as a testament to Silo Pharma s commitment to expanding its intellectual property portfolio. The therapeutic solution, aimed a...
Silo Pharma Advances PTSD and Anxiety Treatment with FDA Pre-IND Submission Report on Latest Developments Biopharmaceutical firm Silo Pharma Inc. has recently made significant strides in the development of innovative treatments for Post-Traumatic Stress Disorder (PTSD) and anxiety. The company has formally submitted a Pre-Investigational New Drug (Pre-IND) application to the U.S. Food and Drug Administration (FDA) for SPC-15, a proprietary and novel intranasal treatment targeting these conditions. Clinical Roadmap Unveiled for SPC-15 The submission marks an important step in Silo Pharma s drug development lifecycle, allowing the company to establish a structured clinical trial framework and communicate its...
Silo Pharma Enters Exclusive License Agreement with MedSpray Pharma BV for Innovative PTSD Treatment Silo Pharma Inc, a prominent pharmaceutical company, recently announced its exclusive license agreement with MedSpray Pharma BV for the intranasal technology used in the development of their groundbreaking SPC-15 treatment for Post-Traumatic Stress Disorder (PTSD). This partnership marks a significant milestone in Silo Pharma s mission to provide innovative and effective solutions for mental health disorders. One of the key elements of this collaboration is MedSpray s patented nose-to-brain intranasal technology, which has been specifically chosen for delivering the SPC-15 drug. This exceptional ...
Silo Pharma Inc’s Comment on Sales, Marketing and Customers
For the years ended December 31, 2025 and 2024, one licensee accounted for 100% of the company's total revenues from customer license fees. The company's vendor license agreements during this period were exclusively with two licensors, UMB and Columbia. The company operates in the rare disease therapeutics industry and faces competition from major pharmaceutical, specialty pharmaceutical, biotechnology companies, academic institutions, governmental agencies, and medical research organizations. Its products compete with existing standard-of-care treatments and emerging therapies. Competitors include established pharmaceutical, biopharmaceutical, and biotechnology firms with greater resources and experience, as well as smaller and early-stage companies, particularly those collaborating with larger companies. There is a growing number of companies focused on discovering new psychedelic compounds. The company and its vendors are subject to extensive government regulations, including those enforced by the FDA and other regulatory authorities, which govern all aspects of drug development, approval, and marketing.
Sources:
Silo Pharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Silo Pharma Inc’s corporate clients.
For your research, we’ve provided 9 tables on Silo Pharma Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
